GO:0004853 uroporphyrinogen decarboxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004853 describes the enzymatic activity that converts uroporphyrinogen-III to coproporphyrinogen-III by removing four carboxyl groups as CO2.
• This reaction is a late step in heme biosynthesis and is catalyzed by uroporphyrinogen decarboxylase (UROD).
• Reduced UROD activity is the hallmark of porphyria cutanea tarda (PCT), the most common human porphyria.
• UROD activity can be inhibited by cytochrome P450-mediated oxidation of uroporphyrinogen, linking environmental exposures to disease.
• Animal and cell models with chemically induced UROD deficiency reproduce uroporphyrin accumulation and provide mechanistic insight.
• Studying GO:0004853 requires combining enzymatic assays, genetic models, and CRISPR-based editing of UROD and related genes.
Description
Uroporphyrinogen decarboxylase activity (GO:0004853) is a molecular function that catalyzes the sequential removal of four carboxyl groups from uroporphyrinogen-III to form coproporphyrinogen-III, releasing four molecules of carbon dioxide. This reaction is a critical step in the heme biosynthetic pathway, which produces heme for hemoglobin, cytochromes, and other essential hemoproteins. The enzyme responsible, uroporphyrinogen decarboxylase (UROD), is highly conserved and its deficiency leads to the accumulation of uroporphyrin, a hallmark of porphyria cutanea tarda (PCT). Researchers study GO:0004853 to understand heme biosynthesis, to diagnose and treat porphyrias, and to investigate how environmental and genetic factors modulate enzyme activity. Because PCT is the most common porphyria, with both sporadic and familial forms, UROD activity serves as a key biomarker and therapeutic target.
uroporphyrinogen decarboxylase activity At A Glance
| GO ID | GO:0004853 |
|---|---|
| GO term | uroporphyrinogen decarboxylase activity |
| Ontology | molecular_function |
| Synonym | porphyrinogen carboxy-lyase activity; porphyrinogen decarboxylase activity; uroporphyrinogen-III carboxy-lyase activity; uroporphyrinogen-III carboxy-lyase (coproporphyrinogen-III-forming); uroporphyrinogen III decarboxylase activity |
| Major function | Catalyzes the conversion of uroporphyrinogen-III to coproporphyrinogen-III with release of 4 CO2 |
| Reaction | uroporphyrinogen-III = coproporphyrinogen + 4 CO2 |
| Pathway | Heme biosynthesis |
| Enzyme | Uroporphyrinogen decarboxylase (UROD) |
| Associated disease | Porphyria cutanea tarda (PCT) |
What Is GO:0004853?
GO:0004853 is defined as the catalysis of the reaction: uroporphyrinogen-III = coproporphyrinogen + 4 CO2. In other words, it is the enzymatic activity that removes four carboxyl groups from uroporphyrinogen-III, converting it to coproporphyrinogen-III while releasing carbon dioxide. This activity is synonymous with porphyrinogen carboxy-lyase activity, porphyrinogen decarboxylase activity, and uroporphyrinogen-III carboxy-lyase activity.
Why Is uroporphyrinogen decarboxylase activity Important in Cell Biology?
GO:0004853 is essential for heme biosynthesis, and its dysfunction directly causes porphyria cutanea tarda, the most common porphyria worldwide. Understanding this activity helps researchers diagnose and manage PCT, develop targeted therapies, and elucidate how environmental factors such as alcohol, estrogens, and polyhalogenated aromatic compounds inhibit UROD. Moreover, because heme is critical for oxygen transport and electron transfer, perturbations in this activity can have broad physiological consequences.
• Deficiency in UROD activity causes porphyria cutanea tarda, characterized by blistering skin lesions and liver dysfunction.
• UROD activity is a diagnostic marker for PCT and other porphyrias.
• The reaction is a key step in heme biosynthesis, affecting hemoglobin and cytochrome production.
• Environmental toxins and drugs can inhibit UROD activity, linking exposure to disease onset.
• Animal models with reduced UROD activity mimic human uroporphyrin accumulation and aid drug testing.
• Genetic mutations in UROD lead to familial PCT, highlighting the importance of enzyme structure-function studies.
• Understanding UROD regulation may reveal therapeutic strategies for PCT and related disorders.
• CRISPR-based editing of UROD enables precise modeling of enzyme deficiency in cell and animal systems.
What Happens During uroporphyrinogen decarboxylase activity?
Substrate Binding and Decarboxylation
In simple terms: The enzyme grabs uroporphyrinogen-III and starts removing its carboxyl groups one by one.
Uroporphyrinogen decarboxylase binds uroporphyrinogen-III and catalyzes the sequential removal of four carboxyl groups from the pyrrole rings, beginning with the ring D acetate group, to form coproporphyrinogen-III. This process releases four molecules of carbon dioxide. The enzyme operates as a monomer and does not require cofactors, but its activity can be influenced by substrate availability and redox conditions.
Order of Decarboxylation
In simple terms: The four carboxyl groups are removed in a specific order, not all at once.
The decarboxylation proceeds in a defined order: the acetate group on ring D is removed first, followed by the acetate on ring A, then the propionate on ring B, and finally the propionate on ring C. This ordered mechanism ensures the correct isomer, coproporphyrinogen-III, is produced. Intermediates with three, two, and one carboxyl group removed can be detected under certain conditions.
Role in Heme Biosynthesis
In simple terms: This step is part of the assembly line that makes heme, the molecule that carries oxygen in blood.
Uroporphyrinogen decarboxylase activity is the fifth step in the heme biosynthetic pathway, converting uroporphyrinogen-III to coproporphyrinogen-III. Subsequent steps convert coproporphyrinogen-III to protoporphyrin IX, which then chelates iron to form heme. Thus, GO:0004853 is essential for producing heme, which is required for hemoglobin, myoglobin, and cytochromes.
Inhibition and Accumulation of Uroporphyrin
In simple terms: When this enzyme is blocked, uroporphyrin builds up and causes skin and liver problems.
Inhibition of uroporphyrinogen decarboxylase activity leads to the accumulation of uroporphyrinogen, which oxidizes to uroporphyrin, a photosensitive compound that causes skin lesions in PCT. Cytochrome P450-mediated oxidation of uroporphyrinogen can inactivate the enzyme, linking drug and alcohol exposure to disease flares. This inhibition mechanism is central to the pathogenesis of sporadic PCT.
Key Genes Involved in GO:0004853 uroporphyrinogen decarboxylase activity
The following genes and proteins are directly or indirectly involved in uroporphyrinogen decarboxylase activity and related pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UROD | Encodes uroporphyrinogen decarboxylase, the enzyme catalyzing GO:0004853 | Mutations cause familial PCT; target for gene editing |
| UROS | Encodes uroporphyrinogen III synthase, upstream of UROD in heme biosynthesis | Defects cause congenital erythropoietic porphyria |
| ALAD | Encodes aminolevulinate dehydratase, early heme biosynthesis enzyme | Deficiency causes ALAD porphyria |
| HMBS | Encodes hydroxymethylbilane synthase, upstream of UROD | Defects cause acute intermittent porphyria |
| CPOX | Encodes coproporphyrinogen oxidase, downstream of UROD | Defects cause hereditary coproporphyria |
| PPOX | Encodes protoporphyrinogen oxidase, downstream of CPOX | Defects cause variegate porphyria |
| FECH | Encodes ferrochelatase, final heme biosynthesis enzyme | Defects cause erythropoietic protoporphyria |
| CYP1A2 | Cytochrome P450 enzyme involved in uroporphyrinogen oxidation | May mediate UROD inhibition by xenobiotics |
| CYP1A1 | Cytochrome P450 enzyme, potential role in uroporphyrinogen oxidation | Studied in models of PCT |
| CYP2E1 | Cytochrome P450 enzyme induced by ethanol | Linked to oxidative stress and UROD inhibition |
| GAPDH | Glycolytic enzyme, sometimes used as control in expression studies | Reference gene in porphyria research |
| ACTB | Beta-actin, common housekeeping gene | Control for gene expression assays |
| HMOX1 | Heme oxygenase 1, degrades heme | Modulates heme pool and may affect UROD expression |
| ALAS1 | Aminolevulinate synthase 1, rate-limiting heme biosynthesis enzyme | Regulated by heme; affects flux through pathway |
| ALAS2 | Erythroid-specific aminolevulinate synthase | Mutations cause X-linked sideroblastic anemia |
| SLC25A38 | Mitochondrial glycine transporter, involved in heme synthesis | Mutations cause sideroblastic anemia |
| ABCB6 | Mitochondrial ATP-binding cassette transporter, involved in porphyrin transport | May influence heme biosynthesis |
| TFRC | Transferrin receptor, iron uptake for heme synthesis | Modulates iron availability for heme |
How Is uroporphyrinogen decarboxylase activity Regulated?
Uroporphyrinogen decarboxylase activity is regulated at multiple levels. UROD gene expression can be influenced by iron status and oxidative stress, and the enzyme itself is susceptible to inactivation by reactive oxygen species generated during cytochrome P450-mediated oxidation of uroporphyrinogen. In sporadic PCT, hepatic UROD activity is decreased without mutations in the UROD gene, often due to acquired factors such as alcohol, hepatitis C, and estrogen use. Additionally, the heme biosynthetic pathway is feedback-regulated by heme at the level of ALAS1, but UROD is not known to be feedback-inhibited by heme.
uroporphyrinogen decarboxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UROD | Porphyria cutanea tarda (familial and sporadic) | UROD knockout or point-mutation cell lines; mouse models |
| UROD | Hepatocellular carcinoma risk in PCT | Liver-specific UROD knockout mice |
| CYP1A2 | Modifies UROD activity via oxidation | CYP1A2 overexpression or knockout hepatocytes |
| UROS | Congenital erythropoietic porphyria | UROS mutant cell models |
| HMBS | Acute intermittent porphyria | HMBS knockout or knock-in models |
Porphyria Cutanea Tarda (PCT)
Porphyria cutanea tarda is the most common porphyria and is caused by decreased uroporphyrinogen decarboxylase activity in the liver. Patients present with blistering skin lesions, fragility, and hypertrichosis. Both familial (due to UROD mutations) and sporadic (acquired) forms exist, with the latter often associated with alcohol, hepatitis C, and iron overload. Diagnosis relies on demonstrating elevated uroporphyrin and reduced UROD activity in erythrocytes or liver.
Hepatocellular Carcinoma
Chronic PCT is associated with an increased risk of hepatocellular carcinoma, likely due to prolonged uroporphyrin accumulation and liver damage. Monitoring of liver function and imaging is recommended in PCT patients. The mechanistic link between UROD deficiency and carcinogenesis is an active area of research.
Other Porphyrias
While GO:0004853 is specifically deficient in PCT, other porphyrias result from defects in different heme biosynthesis enzymes. For example, mutations in UROS cause congenital erythropoietic porphyria, and HMBS defects cause acute intermittent porphyria. Understanding UROD activity in the context of the entire pathway helps differentiate these disorders.
From uroporphyrinogen decarboxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does UROD loss cause uroporphyrin accumulation? | UROD knockout cell lines (e.g., HepG2) |
| Can a specific UROD mutation reproduce PCT? | Point-mutation knock-in mice or cells |
| How does UROD overexpression affect heme synthesis? | UROD overexpression cell lines |
| What is the role of CYP1A2 in UROD inhibition? | CYP1A2 knockout or overexpression models |
| Can CRISPR correct UROD mutations? | Knock-in of wild-type UROD in patient-derived cells |
| How does UROD deficiency affect liver cancer development? | Liver-specific UROD knockout mice |
How to Study the uroporphyrinogen decarboxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC | Uroporphyrin and coproporphyrin levels | Diagnosis of PCT; enzyme activity assays |
| Enzyme activity assay | Conversion of uroporphyrinogen-III to coproporphyrinogen-III | Functional characterization of UROD variants |
| Sanger sequencing | UROD gene mutations | Genetic testing for familial PCT |
| CRISPR-Cas9 knockout | Loss of UROD function | Modeling PCT in cell lines |
| Western blot | UROD protein expression | Evaluating enzyme levels in tissues |
| qRT-PCR | UROD mRNA expression | Gene expression studies |
| Mouse models | In vivo uroporphyrin accumulation and liver pathology | Preclinical testing of therapies |
| Mass spectrometry | Porphyrin profiles and protein modifications | Metabolic profiling in porphyrias |
Enzymatic Activity Assays
Uroporphyrinogen decarboxylase activity is typically measured by incubating cell lysates or purified enzyme with uroporphyrinogen-III and quantifying the formation of coproporphyrinogen-III or the release of CO2 using HPLC or spectrophotometric methods. These assays are essential for diagnosing PCT and for evaluating the effects of mutations or inhibitors.
Genetic and Genomic Approaches
Sanger sequencing and next-generation sequencing of the UROD gene are used to identify mutations in familial PCT. CRISPR-Cas9 genome editing enables the creation of isogenic cell lines with specific UROD mutations or knockouts to study the functional consequences of altered enzyme activity.
Model Organisms
Mouse models with targeted disruption of Urod or chemical inhibition (e.g., using polyhalogenated aromatic compounds) reproduce key features of PCT, including uroporphyrin accumulation and liver damage. These models are valuable for testing therapeutic interventions and understanding disease mechanisms.
Expression and Proteomic Analysis
Quantitative RT-PCR and Western blotting are used to measure UROD mRNA and protein levels in patient samples and cell models. Mass spectrometry-based proteomics can assess global changes in heme biosynthesis enzymes and identify post-translational modifications of UROD.
How CRISPR Can Be Used to Study GO:0004853 uroporphyrinogen decarboxylase activity
Knockout
CRISPR-Cas9 knockout of UROD in hepatocyte cell lines (e.g., HepG2) results in loss of uroporphyrinogen decarboxylase activity, leading to uroporphyrin accumulation and providing a cellular model of PCT. These knockouts are useful for studying the consequences of enzyme deficiency and for screening potential therapeutic compounds.
Point Mutation
Introducing specific point mutations associated with familial PCT (e.g., G281E) into the endogenous UROD locus using CRISPR-Cas9 and homology-directed repair allows researchers to study the functional impact of these mutations on enzyme activity and stability. Such models help distinguish between mild and severe variants.
Knock-in
Knock-in of a tagged UROD (e.g., FLAG or GFP) at the endogenous locus enables real-time tracking of enzyme localization and interaction partners without altering physiological expression levels. This approach is valuable for understanding UROD trafficking and regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of UROD can be used to increase enzyme levels and study the effects on heme biosynthesis flux and uroporphyrin clearance. Overexpression models are useful for testing whether enhancing UROD activity can rescue phenotypes associated with partial deficiency.
How EDITGENE Supports uroporphyrinogen decarboxylase activity Research
Researchers studying uroporphyrinogen decarboxylase activity-related genes often need to determine whether a candidate gene is causally involved in heme biosynthesis or porphyria pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cellular and animal models, enabling functional validation of UROD and related genes.
Contact EDITGENE today to design your custom CRISPR model for uroporphyrinogen decarboxylase activity research.
Frequently Asked Questions About uroporphyrinogen decarboxylase activity
What is uroporphyrinogen decarboxylase activity?
Uroporphyrinogen decarboxylase activity (GO:0004853) is the enzymatic activity that converts uroporphyrinogen-III to coproporphyrinogen-III by removing four carboxyl groups as CO2, a key step in heme biosynthesis.
What genes are involved in uroporphyrinogen decarboxylase activity?
The primary gene is UROD, which encodes the enzyme uroporphyrinogen decarboxylase. Other genes in the heme biosynthesis pathway include UROS, HMBS, CPOX, PPOX, and FECH.
What diseases are associated with uroporphyrinogen decarboxylase activity?
Reduced activity causes porphyria cutanea tarda (PCT), the most common porphyria, characterized by skin blistering and liver dysfunction.
How is uroporphyrinogen decarboxylase activity measured?
It is measured by incubating cell lysates with uroporphyrinogen-III and quantifying the formation of coproporphyrinogen-III using HPLC or spectrophotometric assays.
Can CRISPR be used to study uroporphyrinogen decarboxylase activity?
Yes, CRISPR-Cas9 can create UROD knockouts, point mutations, or knock-ins in cell lines to model PCT and study enzyme function.
What are the symptoms of porphyria cutanea tarda?
Symptoms include blistering skin lesions, fragility, hypertrichosis, and liver abnormalities due to uroporphyrin accumulation.
Is porphyria cutanea tarda inherited?
It can be familial (due to UROD mutations) or sporadic (acquired, often associated with alcohol, hepatitis C, or estrogen use).
How does alcohol affect uroporphyrinogen decarboxylase activity?
Alcohol can induce cytochrome P450 enzymes that oxidize uroporphyrinogen, leading to inhibition of UROD activity and PCT flares.
What animal models exist for uroporphyrinogen decarboxylase deficiency?
Mouse models with Urod knockout or chemical inhibition (e.g., polyhalogenated aromatic compounds) reproduce uroporphyrin accumulation and liver damage.
What is the treatment for porphyria cutanea tarda?
Treatment includes phlebotomy, low-dose hydroxychloroquine, and avoidance of triggering factors like alcohol and estrogens.
Conclusion
Uroporphyrinogen decarboxylase activity (GO:0004853) is a fundamental enzymatic step in heme biosynthesis, and its deficiency is the molecular cause of porphyria cutanea tarda. Understanding the mechanism, regulation, and genetic basis of this activity is essential for diagnosing and treating porphyrias. CRISPR-based models and advanced screening technologies offer powerful tools to dissect UROD function and identify new therapeutic strategies.
References
- 1. Elder GH et al.. 1995. Uroporphyrinogen decarboxylase.. J Bioenerg Biomembr 27(2):207-14 PMID: 7592567
- 2. Mistegård J et al.. 2025. [Porphyria cutanea tarda].. Ugeskr Laeger 187(38) PMID: 41025764
- 3. Bleasel NR et al.. 2000. Porphyria cutanea tarda.. Australas J Dermatol 41(4):197-206; quiz 207-8 PMID: 11105361
- 4. Elder GH. 1998. Porphyria cutanea tarda.. Semin Liver Dis 18(1):67-75 PMID: 9516680
- 5. Lambrecht RW et al.. 1990. Inhibition of uroporphyrinogen decarboxylase activity. The role of cytochrome P-450-mediated uroporphyrinogen oxidation.. Biochem J 269(2):437-41 PMID: 2117439
- 6. Phillips JD. 2019. Heme biosynthesis and the porphyrias.. Mol Genet Metab 128(3):164-177 PMID: 31326287
- 7. Elder GH et al.. 1978. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda.. N Engl J Med 299(6):274-8 PMID: 661926
- 8. Lambrecht RW et al.. 1988. Hepatic uroporphyrin accumulation and uroporphyrinogen decarboxylase activity in cultured chick-embryo hepatocytes and in Japanese quail (Coturnix coturnix japonica) and mice treated with polyhalogenated aromatic compounds.. Biochem J 253(1):131-8 PMID: 3138981
